Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 1,409 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 1,409 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $20.01, for a total value of $28,194.09. Following the transaction, the insider now owns 163,588 shares in the company, valued at $3,273,395.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Natarajan Sethuraman also recently made the following trade(s):

• On Wednesday, November 13th, Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.04, for a total value of $54,108.00.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $19.96 on Thursday. The business has a fifty day moving average price of $16.62 and a 200 day moving average price of $15.85. Entrada Therapeutics, Inc. has a one year low of $10.75 and a one year high of $20.49. The company has a market cap of $746.90 million, a P/E ratio of 12.55 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. As a group, sell-side analysts predict that Entrada Therapeutics, Inc. will post 1.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after acquiring an additional 18,625 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Entrada Therapeutics by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock worth $2,972,000 after acquiring an additional 23,643 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Entrada Therapeutics by 132.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after acquiring an additional 78,953 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after acquiring an additional 14,838 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on TRDA shares. Oppenheimer increased their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright increased their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.